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ABSTRACT
As a widely used anticancer drug, cis-
diamminedichloroplatinum(II) (cisplatin) reacts with
adjacent purine bases in DNA to form predominantly
cis-[Pt(NH3)2{d(GpG)-N7(1),-N7(2)}] intrastrand
cross-links. Drug resistance, one of the major
limitations of cisplatin therapy, is partially due to
the inherent ability of human Y-family DNA poly-
merases to perform translesion synthesis in the
presence of DNA-distorting damage such as cis-
platin–DNA adducts. To better understand the
mechanistic basis of translesion synthesis contri-
buting to cisplatin resistance, this study investi-
gated the bypass of a single, site-specifically placed
cisplatin-d(GpG) adduct by a model Y-family DNA
polymerase, Sulfolobus solfataricus DNA polymer-
ase IV (Dpo4). Dpo4 was able to bypass this double-
base lesion, although, the incorporation efficiency
of dCTP opposite the first and second cross-linked
guanine bases was decreased by 72- and 860-fold,
respectively. Moreover, the fidelity at the lesion
decreased up to two orders of magnitude. The
cisplatin-d(GpG) adduct affected six downstream
nucleotide incorporations, but interestingly the
fidelity was essentially unaltered. Biphasic kinetic
analysis supported a universal kinetic mechanism
for the bypass of DNA lesions catalyzed by various
translesion DNA polymerases. In conclusion, if
human Y-family DNA polymerases adhere to this
bypass mechanism, then translesion synthesis by
these error-prone enzymes is likely accountable for
cisplatin resistance observed in cancer patients.
INTRODUCTION
cis-Diamminedichloroplatinum(II) (cisplatin, DDP) is
a potent anticancer drug that is eﬀective for the treatment
of testicular, ovarian, head, neck, and nonsmall cell
lung cancers. During the biotransformation of cisplatin
in vitro and in vivo, cisplatin reacts with the N7 position of
purines to generate several possible adducts: cis-[Pt(NH3)2
{d(GpG)-N7(1),-N7-(2)}] intrastrand cross-links (cis-
platin-d(GpG)), cis-[Pt(NH3)2{d(ApG)-N7(1),-N7-(2)}]
intrastrand cross-links, cis-[Pt(NH3)2 {d(GpNpG)-
N7(1),-N7-(3)}] intrastrand cross-links, 1,3-interstrand
cross-links with guanines and monofunctional cross-links
with guanine (1–4). These cisplatin–DNA adducts can
severely inhibit DNA replication, thereby highlighting this
cytotoxic eﬀect as an important mode of drug action.
Upon encountering a cisplatin–DNA adduct in vitro,
replicative DNA polymerases, e.g. eukaryotic DNA
polymerases a (5,6), d (6) and e (7), stall while most
DNA repair and lesion bypass polymerases can traverse
the lesion. Y-family DNA polymerases, characterized by
low ﬁdelity and processivity, are notorious for bypassing
DNA lesions. Of the four Y-family members in humans,
DNA polymerase Z (PolZ) bypasses cisplatin–DNA
adducts in a relatively eﬃcient and error-free manner
in vitro (8–11), and cell-based assays provide additional
evidence that PolZ is involved in the bypass of this adduct
in vivo (12–14). DNA polymerases i (Poli) (15) and k
(Polk) (16,17) are impeded by cisplatin–DNA adducts,
however, it remains to be explored whether bypass is
possible via the two-polymerase model of lesion bypass
(18,19). Recent studies provide evidence that Rev1, both a
deoxycytidyl transferase and structural factor during
replication, modulates cisplatin mutagenicity (20,21), but
the catalytic activity appears to be dispensable (22). Other
relevant eukaryotic DNA polymerases implicated in the
bypass of cisplatin–DNA adducts are DNA polymerases g
(23),   (23–25), b (6,10,11,26–28) and m (29). Finally, a
variety of cellular processes have been proposed to
promote cancer cell survival, which contributes to clinical
drug resistance associated with cisplatin. Some of these
in vivo processes are the following: reduced drug uptake,
enhanced drug inactivation, increased DNA repair,
disabled apoptotic signaling machinery and translesion
DNA synthesis (TLS) [see reviews in refs (30–34) for
a comprehensive overview of postulated mechanisms].
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design improved anticancer drugs, it is imperative to
understand the eﬀect of cisplatin as it pertains to lesion
bypass at the molecular level.
For this study, we investigated the mechanistic basis of
lesion bypass catalyzed by Sulfolobus solfataricus DNA
polymerase IV (Dpo4) for a single, site-speciﬁcally placed
cisplatin-d(GpG) adduct using pre-steady state kinetics.
Utilizing this methodology, we have previously established
(i) the minimal kinetic mechanism and ﬁdelity of Dpo4
incorporating a single nucleotide into undamaged DNA
(35,36) and (ii) the mechanistic basis of Dpo4 bypassing
an abasic site, which is a prototype single-base lesion (37).
To provide a deeper mechanistic understanding of how
Y-family DNA polymerases catalyze the bypass of other
DNA lesions, we used the cisplatin-d(GpG) adduct as a
model double-base lesion and Dpo4 as a model Y-family
DNA polymerase. Among the aforementioned cisplatin–
DNA adducts, cisplatin-d(GpG) is the predominant
species ( 65%) and has been correlated with clinical
eﬃcacy of the drug (2,38,39). Although Dpo4 shares
more sequence similarity with Polk as a DinB homolog,
one study suggests that the lesion bypass properties of
Dpo4 are more similar to PolZ (40). Consequently,
establishing the kinetic mechanism of Dpo4 bypassing
the cisplatin-d(GpG) adduct may (i) establish the mechan-
istic basis of double-base lesion bypass, (ii) illuminate the
molecular basis of drug resistance due to cisplatin bypass,
(iii) assess the mutagenic potential of inducing secondary
malignancies and (iv) enable scientists to design more
eﬀective anticancer drugs.
MATERIALS AND METHODS
Reaction buffers
Optimized reaction buﬀer D contains the following:
50mM HEPES (pH 7.5 at 378C), 5mM MgCl2,5 0 m M
NaCl, 5mM DTT, 10% glycerol, 0.1mM EDTA and
0.1mg/ml bovine serum albumin (BSA) (36). For the gel
mobility shift assay, reaction buﬀer E contains the
following: 50mM Tris–Cl (pH 7.5 at 238C), 5mM
MgCl2, 50mM NaCl, 5mM DTT, 10% glycerol and
0.1mg/ml BSA. All reported concentrations were the ﬁnal
concentrations upon mixing. All reactions, unless noted,
were performed at 378C.
DNA substrates
The cisplatinated-DNA oligonucleotide (Table 1) was
modiﬁed, ligated and puriﬁed previously (41). All DNA
primers (Table 1) were prepared previously (41) except
for the 21-mer purchased from Integrated DNA
Technologies, Inc., Coralville, IA and subsequently gel
puriﬁed. The DNA primers were 50-radiolabeled with
[g-
32P]ATP (GE Healthcare, Picataway, NJ, USA) and
Optikinase (USB) (36). To anneal, the [
32P]-radiolabeled
DNA primer and unlabeled template were combined at a
1:1.15 molar ratio, respectively, heated to 858C for 6min
and cooled slowly to room temperature.
Running startassay
Using a rapid-chemical quench ﬂow apparatus (KinTek),
a solution of preincubated Dpo4 (100nM) and 50-[
32P]
DNA (100nM) was mixed with an equal volume (15ml) of
all four dNTPs (200mM each) in buﬀer D and quenched
with 0.37M EDTA at times ranging from ms to min. The
incorporation pattern was resolved via denaturing poly-
acrylamide gel electrophoresis (PAGE).
Electrophoretic mobility shiftassay(EMSA)
To determine the Kd
DNA for the Dpo4 DNA binary
complex, Dpo4 (15–600nM) was added to a solution
containing 50-[
32P] DNA (100nM) in buﬀer E and allowed
to equilibrate for 15min at 238C. Then, the binary com-
plex was separated from unbound DNA using a 4.5%
native polyacrylamide gel with a running buﬀer as
described previously (37) and quantitated using a
PhosphorImager 445 SI (Molecular Dynamics,
Sunnyvale, CA, USA). A plot of binary complex
formation versus the concentration of Dpo4 was ﬁt to
Equation 1
E   DNA ½  ¼ 0:5 KDNA
d þ E0 þ D0
  
  0:5 KDNA
d þ E0 þ D0
   2
 4E0D0
hi 1=2
1
where E0 and D0 represent the active enzyme and DNA
concentrations, respectively.
Determination ofthe kpandKdofan incoming nucleotide
A pre-equilibrated solution of Dpo4 (120nM) and 50-[
32P]
DNA (30nM) in buﬀer D was combined with increas-
ing concentrations of a single dNTP (25–1600mM) in
buﬀer D. Aliquots of the reaction mixtures were quenched
at various times using 0.37M EDTA. For fast reaction
times, a rapid-chemical quench ﬂow apparatus was used.
Reaction products were resolved using sequencing gel
electrophoresis and quantitated with a PhosphorImager
Table 1. DNA sequences of primers and templates
Primers
19-mer 50-GTCCCTGTTCGGGCGCCAG-30
21-mer 50-GTCCCTGTTCGGGCGCCAGGA-30
22-mer 50-GTCCCTGTTCGGGCGCCAGGAG-30
23-mer 50-GTCCCTGTTCGGGCGCCAGGAGA-30
24-mer 50-GTCCCTGTTCGGGCGCCAGGAGAC-30
25-mer 50-GTCCCTGTTCGGGCGCCAGGAGACC-30
26-mer 50-GTCCCTGTTCGGGCGCCAGGAGACCA-30
27-mer 50-GTCCCTGTTCGGGCGCCAGGAGACCAG-30
28-mer 50-GTCCCTGTTCGGGCGCCAGGAGACCAGA-30
29-mer 50-GTCCCTGTTCGGGCGCCAGGAGACCAGAG-30
30-mer 50-GTCCCTGTTCGGGCGCCAGGAGACCAGAGG-30
31-mer 50-GTCCCTGTTCGGGCGCCAGGAGACCAGAGGC-30
32-mer 50-GTCCCTGTTCGGGCGCCAGGAGACCAGAGG
CT-30
Templates
44DDP
a 30-CAGGGACAAGCCCGCGGTCCTCTGGTCTCCGAT
CAGAGCACTAG-50
44CTL 30-CAGGGACAAGCCCGCGGTCCTCTGGTCTCCGAT
CAGAGCACTAG-50
aThe cisplatin-modiﬁed guanines are in bold.
3868 Nucleic Acids Research, 2008, Vol. 36, No. 12445 SI. The time course of product formation at each
nucleotide concentration was ﬁt to a single-exponential
equation (Equation 2) using a nonlinear regression
program, KaleidaGraph (Synergy Software, Essex
Junction, VT, USA).
Product ½  ¼ A1  exp  kobst ðÞ ½  2
A represents the reaction amplitude. The extracted values
for the observed rate constant (kobs) of nucleotide incor-
poration were plotted as a function of dNTP Mg
2+ con-
centration and ﬁt to a hyperbolic equation (Equation 3)
kobs ¼ kp½dNTP =f½dNTP þKdg 3
which resolved the kp and Kd values for nucleotide
incorporation. The substrate speciﬁcity (kp/Kd), eﬃciency
ratio [(kp/Kd)control/(kp/Kd)damaged], and ﬁdelity {(kp/
Kd)incorrect/[(kp/Kd)correct+(kp/Kd)incorrect]} were then
calculated.
Biphasic kineticassays
A pre-equilibrated solution of Dpo4 (120nM) and 50-[
32P]
DNA (30nM) in buﬀer D was mixed with a DNA trap
[5mM, 21-mer/41CTL D-1 (36)] and dNTP (1.0mM) in
buﬀer D supplemented with Mg
2+, which may be chelated
by the DNA trap as previously described (37). A rapid
chemical quench ﬂow apparatus was used to quench
aliquots of the reaction mixtures at various times using
0.37M EDTA. Reaction products were resolved and
quantitated as described earlier. The concentration of
product formation was graphed as a function of time and
ﬁt to a double-exponential equation (Equation 4) using
KaleidaGraph.
Product ½  ¼ E0A1 1   exp  k1t ðÞ ½  þ E0A2 1   exp  k2t ðÞ ½ 
4
E0 represents the total enzyme concentration, A1 and A2
represent the ﬁrst and second phase reaction amplitudes,
respectively, and k1 and k2 represent the ﬁrst and second
phase rate constants, respectively.
RESULTS
Bypassof acisplatin-d(GpG) adduct
We have previously constructed a 44-mer DNA template
(44DDP) containing a site-speciﬁc cisplatin-d(GpG)
adduct (Table 1) (41). To generate a nucleotide incorpora-
tion proﬁle using this adduct-containing DNA substrate,
we ﬁrst performed a ‘running start’ assay (see Materials
and methods section) to visualize the extension of the
50-[
32P]-labeled 19-mer/44DDP (Table 1) catalyzed by
Dpo4 in the presence of all four dNTPs (Figure 1B).
Our results showed that Dpo4 bypassed the single
cisplatin-d(GpG) adduct, as full-length product (44-mer)
was detected at 60s (Figure 1B). Although Dpo4 syn-
thesized full-length product, the signiﬁcant accumulation
of intermediate products revealed two distinct pause
sites (23- and 24-mers) corresponding to nucleotide incor-
porations opposite the cisplatin-d(GpG) adduct. In com-
parison, Dpo4 did not pause at these positions in the
control experiment with an undamaged DNA substrate
(19-mer/44CTL, Table 1) in which full-length product was
generated within 10s (Figure 1A). The purity of 44DDP
was examined to ensure that the bypass products in
Figure 1B were not due to a subpopulation of unmodiﬁed
or deplatinated 44-mer (Supplementary Figure 1). Also
notable, the observation of 45- and 46-mer products
suggested Dpo4 catalyzed template-independent nucleo-
tide incorporations (Figure 1) (42). However, this result
warrants further investigation due to the possibility of
nucleotide deletions, nucleotide additions or other com-
plex transactions occurring in the vicinity of the lesion as
previously demonstrated (10,26,43–47).
Binding ofDpo4to cisplatin-modified DNA
Various structural studies reveal a signiﬁcant bend in the
DNA,  40–808, which may preclude binary complex
formation (48–50). Since the two strong pause sites occur
opposite the cisplatin-d(GpG) lesion, it is possible that a
weaker binding aﬃnity of Dpo4 to DNA may be a
contributing factor. Therefore, we determined the equi-
librium dissociation constant (Kd
DNA) of several binary
complexes using the EMSA (see Materials and methods
section). EMSA has been proven to be a reliable assay for
estimating the Kd
DNA value of the Dpo4 DNA binary
complex (37,42). By varying the primer length, a series of
DNA substrates was designed to mimic the progression of
DNA synthesis catalyzed by Dpo4 as it approached,
encountered and bypassed the damaged site. For example,
to measure the Kd
DNA value at the second pause site
(Figure 1B), we titrated increasing concentrations of Dpo4
into a ﬁxed concentration of 50-[
32P]-labeled 24-mer/
44DDP (Table 1). After equilibration, the binary complex
Dpo4 24-mer/44DDP and free DNA were separated via
native PAGE (Figure 2A). Next, the concentration of
binary complex formation was plotted versus Dpo4
concentration (Figure 2B) and ﬁt to a quadratic equation
(Equation 1), which yielded a Kd
DNA of 26 3nM
(Table 2). Similarly, the Kd
DNA for the Dpo4 24-mer/
44CTL (Table 1) binary complex was measured to be
8 1nM, and the aﬃnity ratio [(Kd
DNA)damaged/
(Kd
DNA)control] was calculated to be 3.3-fold (Table 2).
Analysis of the ﬁrst strong pause site (23-mer/44DDP)
and the ﬁrst downstream, nonpause site (25-mer/44DDP)
revealed a similar eﬀect on the Kd
DNA value (Table 2).
Dpo4 binding upstream of the cisplatin lesion was
unaﬀected, yet the binding aﬃnity downstream was
not restored until the second downstream site (Table 2).
These modest,  3-fold lower aﬃnity values indicated that
the overall binding aﬃnity of Dpo4 to a cisplatin-d(GpG)
adduct was not signiﬁcantly aﬀected and was localized to
the vicinity of the lesion. Furthermore, these results
suggested that the association and dissociation rates of
DNA from the Dpo4 DNA complex at or near the
double-base lesion were not signiﬁcantly altered, and
the pausing of Dpo4 observed in Figure 1 was not due to
the faster dissociation of the Dpo4 DNA complex. This
conclusion was supported by the biphasic kinetics of
nucleotide incorporations at the pause sites in the presence
of a DNA trap (see Biphasic kinetics section). Thus, we
Nucleic Acids Research, 2008, Vol. 36, No. 12 3869hypothesized that the structurally distorted DNA signi-
ﬁcantly decreased the incorporation eﬃciency of an
incoming nucleotide at the aforementioned pause sites.
Efficiency of nucleotide incorporation opposite
acisplatin-d(GpG) adduct
Transient state kinetics performed under single-turnover
conditions measures the maximum incorporation rate (kp)
and the equilibrium dissociation constant (Kd) of nucleo-
tide incorporation which are the two deﬁning kinetic
parameters of catalytic eﬃciency or substrate speciﬁcity
(kp/Kd). To resolve the kp and Kd at the second pause site,
a solution containing Dpo4 (120nM) was preincubated
with 50-[
32P]-labeled 24-mer/44DDP (30nM) before initi-
ating the reaction with increasing concentrations of dCTP
for various times (see Materials and methods section).
A primary plot of product concentration versus time
conformed to a single-exponential ﬁt (Equation 2) so that
the kobs values were extracted for each dCTP concen-
tration (Figure 3A and Supplementary Figure 2). Then,
a secondary plot of the kobs values versus dCTP
concentration was ﬁt to Equation 3 which yielded a kp
of 0.043 0.004s
 1 and a Kd of 588 145mM (Figure 3B
and Table 3). The calculated substrate speciﬁcity of
7.3 10
 5mM
 1s
 1 was  860-fold lower than dCTP
incorporation into undamaged 24-mer/44CTL (Tables 3
and 4). Any bias due to a DNA sequence-dependent eﬀect
was attenuated by determining the kinetic parameters for
Figure 1. Running start nucleotide incorporation assay. A pre-equilibrated solution of Dpo4 (100nM) and 50-[
32P]-labeled DNA (100nM) were mixed
with all four dNTPs (200mM each) for various reaction times before terminating with EDTA. Lengths of the resolved products and the site of the cisplatin
adduct (asterisk) are designated along the right margin. (A) Reaction with 19-mer/44CTL substrate; (B) reaction with 19-mer/44DDP substrate.
0
20
40
60
80
100
A
B
0 100 200 300 400 500 600
D
p
o
4
 
2
4
-
m
e
r
/
4
4
C
P
 
(
n
M
)
Dpo4  (nM)
Figure 2. Measurement of Dpo4 binding to 24-mer/44DDP. (A)
Reactions containing 50-[
32P]-labeled 24-mer/44DDP (100nM) were
incubated with increasing concentrations of Dpo4 (25–600nM). The
binary complex was separated from the unbound DNA substrate via
native polyacrylamide gel electrophoresis. (B) A plot of binary complex
formation (Dpo4 24-mer/44DDP) versus Dpo4 concentration was ﬁt to a
quadratic equation (Equation 1), which yielded a Kd
DNA of 26 3nM.
3870 Nucleic Acids Research, 2008, Vol. 36, No. 12all correct incorporations into 44CTL, and these results
indicated that the incorporation eﬃciency varied over a
30-fold range (Table 4). Furthermore, the substrate speci-
ﬁcity for dCTP incorporation into 23-mer/44DDP was
reduced by 72-fold relative to the control DNA substrate
23-mer/44CTL (Tables 3 and 4). Please note, these are
apparent kp and Kd values at the strong pause sites due
to the detection of biphasic kinetics of nucleotide
incorporation at these sites (see Discussion section).
Misincorporation at the two strong pause sites opposite
the cisplatin cross-linked guanines followed similar trends
in which (i) the order of preferred dNTP incorporation
was dATP>dTTP>dGTP, (ii) the kp/Kd values were in
the range of 10
 6 to 10
 7mM
 1s
 1 and (iii) the ﬁdelity
was in the low range of 10
 4 to 10
 3 at the 30-dG site and
10
 3 to 10
 2 at the 50-dG site (Table 3). Collectively, these
kinetic data supported our hypothesis that a decreased
nucleotide incorporation eﬃciency explained the signiﬁ-
cant product accumulation induced by the cisplatin–DNA
adduct (Figure 1B and Table 3).
Efficiency of nucleotide incorporation proximal
to thecisplatin-d(GpG) adduct
In parallel single-turnover experiments, the substrate
speciﬁcity for events both upstream and downstream
from the lesion was kinetically examined using a series of
DNA primers with the same cisplatinated or control DNA
templates (Table 1). The eﬃciency ratio, deﬁned as the
substrate speciﬁcity for the control DNA divided by the
substrate speciﬁcity for damaged DNA, provides a foun-
dation for our kinetic comparisons. All upstream events
were essentially normal (eﬃciency ratios of 1.1 and 1.5),
while the downstream events revealed an intriguing trend
(Figure 4A). Interestingly, the incorporation eﬃciency did
not gradually decrease as a linear function before
resuming to normal. Instead, the most signiﬁcant down-
stream perturbation occurred at the  2 and  3 positions
relative to the cisplatinated 50-dG (Table 3 and
Figure 4A). At these ‘weak’ pause sites, the eﬃciency
ratio for correct dNTP incorporation into 26-mer/44DDP
and 27-mer/44DDP was decreased by 36- and 17-fold,
respectively, but there was not a dramatic eﬀect on ﬁdelity
(Table 3 and Figure 4B). In addition, these ‘weak’ pause
sites were observable in the running start assay as a minor
accumulation of intermediate products (26- and 27-mers)
(Figure 1B). Other notable sites in which Dpo4 appeared
to pause during dNTP incorporation include 25-mer/
44DDP, 29-mer/44DDP and 30-mer/44DDP (Figure 4A).
Slowing the rate of maximum nucleotide incorporation
lead to a waning of the substrate speciﬁcity in an
unprecedented cyclic pattern during the downstream
extension steps. These observations reinforced the kinetic
impact of a severely distorted DNA molecule within or
near the active site of a DNA polymerase (48–50). Overall,
the catalytic eﬃciency of Dpo4 synthesizing on a cisplatin-
modiﬁed DNA substrate returned to normal after seven
downstream incorporations (Table 3 and Figure 4A).
Biphasickinetics
Biphasic kinetic analysis is useful for extracting the rate
constants and amplitudes for reactions in which distinct
Table 2. Binding aﬃnity of Dpo4 to control and damaged DNA
substrates at 238C
Damaged substrate Kd
DNA
(nM)
Control substrate Kd
DNA
(nM)
Aﬃnity
ratio
a
21-mer/44DDP 8 1 21-mer/44CTL 18 3 0.4-fold
22-mer/44DDP 21 4 22-mer/44CTL 16 3 1.3-fold
23-mer/44DDP
b 56 9 23-mer/44CTL 17 2 3.3-fold
24-mer/44DDP
b 26 3 24-mer/44CTL 8 1 3.3-fold
25-mer/44DDP 17 4 25-mer/44CTL 5 1 3.4-fold
26-mer/44DDP 12 2 26-mer/44CTL 11 2 1.1-fold
27-mer/44DDP 17 3 27-mer/44CTL 13 4 1.3-fold
aCalculated as (Kd
DNA)damaged/(Kd
DNA)control.
bDNA substrates at strong pause sites.
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Figure 3. Concentration dependence on the pre-steady state rate
constant of dCTP incorporation. A preincubated solution of Dpo4
(120nM) and 50-[
32P]-labeled 24-mer/44DDP (30nM) was rapidly
mixed with increasing concentrations of dCTP Mg
2+ (100mM, open
triangle; 200mM, ﬁlled triangle; 400mM, open square; 700mM, ﬁlled
square; 1300mM, open circle; 1600mM, closed circle) for various time
intervals. (A) The solid lines represent the best ﬁts to a single
exponential (Equation 2), which determined the observed rate
constants, kobs. Plots for each dCTP time course are provided in
Supplementary Figure 2. (B) The kobs values were plotted as a function
of dCTP concentration and ﬁt to a hyperbolic (Equation 3), whereby
a kp of 0.043 0.004s
 1 and a Kd of 588 145mM were obtained.
Nucleic Acids Research, 2008, Vol. 36, No. 12 3871phases may be hidden during dNTP incorporation due to
the inability to isolate diﬀerent DNA polymerase binding
modes (37,41). The amplitude of the ﬁrst phase represents
the fraction of E DNA bound in a productive mode,
whereas the amplitude of the second phase represents the
nonproductively bound fraction that is slowly converted
into a productive mode (Scheme 1) (37,41). Thus, exam-
ining biphasic kinetics advances our mechanistic under-
standing of the events occurring at the active site of a
Y-family DNA polymerase upon encountering a cis-
platin–DNA adduct. To perform this assay, a preincu-
bated solution of Dpo4 (120nM) and 50-[
32P]-labeled
23-mer/44DDP (30nM) was mixed with a solution of 21-
mer/41CTL D-1 DNA trap (5mM) and dCTP Mg
2+
(1.0mM) for various times before being quenched with
0.37M EDTA (see Materials and methods section). The
purpose of the unlabeled D-1 trap is to sequester any
Dpo4 molecules that dissociate from the damaged DNA
substrate so that product formation is solely due to a
single-binding event. The eﬀectiveness of the D-1 DNA
trap was tested and conﬁrmed to be suﬃcient (see
Supplementary Figure 3). A plot of product concentration
as a function of time (Figure 5) was ﬁt to Equation 4,
which yielded the following kinetic parameters:
A1=2.1 0.1nM (7%), k1=10 2s
 1, A2=19 1nM
(63%), k2=0.0009 0.0001s
 1 (Table 5). Indeed,
Table 3. Kinetic parameters of nucleotide incorporation into cisplatin-modiﬁed DNA
DNA substrate (P/T) dNTP kp
a(s
 1) Kd
a (mM) kp/Kd (mM
 1s
 1) Eﬃciency ratio
b Fidelity
c
21-mer/44DDP dGTP 6.0 0.2 (2.0 0.2) 10
2 3.0 10
 2 1.5 –
dATP 0.026 0.002 (1.0 0.1) 10
3 2.7 10
 5 0.97 9.1 10
 4
dCTP 0.039 0.007 (6 3) 10
2 6.7 10
 5 2.6 2.3 10
 3
dTTP 0.011 0.001 (1.3 0.2) 10
3 8.6 10
 6 1.4 2.9 10
 4
22-mer/44DDP dATP 3.8 0.2 (3.9 0.7) 10
2 9.8 10
 3 1.1 –
dCTP 0.0041 0.0004 (1.4 0.2) 10
3 2.9 10
 6 29 2.9 10
 4
dGTP 0.0081 .0009 (1.1 0.2) 10
3 7.1 10
 6 10 7.2 10
 4
dTTP 0.0021 0.0002 (7 2) 10
2 3.2 10
 6 5.5 3.3 10
 4
23-mer/44DDP dCTP 1.6 0.2 (1.3 0.2) 10
3 1.3 10
 3 72 –
dATP 0.0056 0.0005 (7 1) 10
2 8.0 10
 6 3.4 6.3 10
 3
dGTP 0.00050 0.00008 (6 2) 10
2 9.1 10
 7 67 7.2 10
 4
dTTP 0.0017 0.0003 (6 2) 10
2 2.8 10
 6 21 2.2 10
 3
24-mer/44DDP dCTP 0.043 0.004 (6 1) 10
2 7.3 10
 5 860 –
dATP 0.00265 0.00009 (4.6 0.4) 10
2 5.7 10
 6 4.7 7.3 10
 2
dGTP 0.000171 0.000008 (8.0 0.8) 10
2 2.1 10
 7 290 2.9 10
 3
dTTP 0.00075 0.00003 (6.4 0.7) 10
2 1.2 10
 6 51 1.6 10
 2
25-mer/44DDP dATP 9.6 0.4 (5.8 0.6) 10
2 1.6 10
 2 6.1 –
dCTP 0.031 0.004 (1.6 0.3) 10
3 1.9 10
 5 4.4 1.2 10
 3
dGTP 0.0115 0.0009 (1.1 0.2) 10
3 1.0 10
 5 6.8 6.3 10
 4
dTTP 0.025 0.003 (1.3 0.2) 10
3 1.9 10
 5 0.92 1.2 10
 3
26-mer/44DDP dGTP 1.9 0.1 (4.0 0.7) 10
2 4.7 10
 3 36 –
dATP 0.04 0.01 (1.5 0.8) 10
3 2.7 10
 5 0.98 5.6 10
 3
dCTP 0.007 0.002 (1.4 0.5) 10
3 5.0 10
 6 35 1.1 10
 3
dTTP 0.0032 0.0006 (1.1 0.4) 10
3 2.8 10
 6 4.3 6.0 10
 4
27-mer/44DDP dATP 0.20 0.02 (2.7 0.7) 10
2 7.5 10
 4 17 –
dCTP 0.0016 0.0003 (8 3) 10
2 2.1 10
 3 40 2.8 10
 3
28-mer/44DDP dGTP 4.4 0.3 (5.0 0.9) 10
2 8.9 10
 3 2.8 –
dATP 0.0057 0.0006 (1.5 0.3) 10
3 3.9 10
 6 6.7 4.3 10
 4
29-mer/44DDP dGTP 0.72 0.05 (5.0 0.9) 10
2 1.4 10
 3 4.0 –
dATP 0.0016 0.0001 (6 1) 10
2 2.8 10
 6 9.4 1.9 10
 3
30-mer/44DDP dCTP 3.3 0.2 (2.7 0.4) 10
2 1.2 10
 2 7.1 –
dGTP 0.0022 .0002 (9 2) 10
2 2.5 10
 6 25 2.0 10
 4
31-mer/44DDP dTTP 5.5 0.3 (1.5 0.3) 10
2 3.7 10
 2 2.1 –
dCTP 0.019 0.003 (1.0 0.3) 10
3 1.8 10
 5 0.69 4.9 10
 4
32-mer/44DDP dATP 18.9 0.8 (1.3 0.2) 10
2 1.5 10
 1 0.53 –
dCTP 0.032 0.002 (8 1) 10
2 3.9 10
 5 2.2 2.6 10
 4
aThe kp and Kd obtained with 23-mer/44DDP and 24-mer/44DDP are apparent kinetic parameters due to biphasic kinetics of nucleotide
incorporations at these pause sites.
bCalculated as (kp/Kd)control/(kp/Kd)damaged in which the (kp/Kd)control is derived from Table 4 or ref. (36) for correct and incorrect incorporations,
respectively.
cCalculated as (kp/Kd)incorrect/[(kp/Kd)correct+(kp/Kd)incorrect].
Table 4. Kinetic parameters of correct nucleotide incorporation into
the 44CTL DNA template
DNA substrate
(P/T)
dNTP kp (s
 1) Kd (mM) kp/Kd
(mM
 1s
 1)
21-mer/44CTL dGTP 9.3 0.2 (2.1 0.2) 10
2 4.5 10
 2
22-mer/44CTL dATP 4.1 0.1 (3.8 0.4) 10
2 1.1 10
 2
23-mer/44CTL dCTP 10.8 0.4 (1.2 0.1) 10
2 9.3 10
 2
24-mer/44CTL dCTP 4.5 0.2 (7 2) 10
1 6.3 10
 2
25-mer/44CTL dATP 15.4 0.8 (1.6 0.3) 10
2 9.7 10
 2
26-mer/44CTL dGTP 9.3 0.2 (5.5 0.4) 10
1 1.7 10
 1
27-mer/44CTL dATP 5.8 0.2 (4.0 0.5) 10
2 1.3 10
 2
28-mer/44CTL dGTP 15.0 0.8 (6.1 0.8) 10
2 2.5 10
 2
29-mer/44CTL dGTP 5.2 0.5 (9 2) 10
2 5.6 10
 3
30-mer/44CTL dCTP 14.5 0.9 (1.7 0.3) 10
2 8.5 10
 2
31-mer/44CTL dTTP 15.7 0.9 (2.0 0.4) 10
2 7.7 10
 2
32-mer/44CTL dATP 21 1 (2.6 0.4) 10
2 8.0 10
 2
3872 Nucleic Acids Research, 2008, Vol. 36, No. 12biphasic kinetics was observed at the cisplatin cross-linked
30-dG, whereby nucleotide incorporation initially pro-
ceeded with a fast phase of low amplitude followed by a
slow phase of large amplitude. It is conceivable that the
fast phase was due to unmodiﬁed or deplatinated 44-mer;
however, this is unlikely because (i) 44DDP has been
puriﬁed to apparent homogeneity (Supplementary
Figure 1) and (ii) platinum adducts are stable under
harsh temperature and pH conditions (51). Interestingly, a
diﬀerent biphasic trend emerged at the second strong
pause site as evident by these kinetic values:
A1=1.11 0.01nM (3.7%), k1=4.0 0.7s
 1,A 2=3.2
 0.4nM (11%), k2=0.00016 0.00003s
 1 (Table 5 and
Figure 5). These results indicated that a minute portion of
Dpo4 rapidly incorporated dCTP into the Dpo4 24-mer/
44DDP complex, while most of Dpo4 either dissociated or
failed to achieve a catalytically competent complex. Thus,
these biphasic kinetic assays provided a basis for explain-
ing the more signiﬁcant reduction in catalytic eﬃciency
(72- versus 860-fold) for the two strong pause sites. As
proof of principle, nucleotide incorporation into a
nonpause site, 21-mer/44DDP, exhibited a single fast
A
B
Figure 4. Quantitative eﬀect of the cisplatin–DNA adduct on nucleo-
tide incorporation and ﬁdelity. (A) A plot of the eﬃciency ratio
(extracted from Table 3) for each correct incorporation into DNA
substrates with varying primer lengths is shown. (B) The ﬁdelity of
all misincorporations into undamaged [bottom most row, from ref.
(36)] and damaged (upper rows) DNA by Dpo4 are shown. The
two dashed vertical lines represent the outermost limits of ‘normal’
misincorporations by Dpo4. Each shape designates a speciﬁc
dNTP: dATP, ﬁlled circle; dCTP, ﬁlled triangle; dGTP, ﬁlled square;
dTTP, ﬁlled diamond. Asterisks indicate values from ref. (36).
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Figure 5. Biphasic kinetics observed in the presence of a DNA trap
when Dpo4 incorporated dCTP opposite the cisplatin lesion. A
preincubated solution of Dpo4 (120nM) and 50-[
32P]-labeled DNA
(30nM) was rapidly mixed with 1.0mM dCTP Mg
2+ in the presence
of a DNA trap (5mM) for various time intervals. Applying a double
exponential (Equation 4) to a plot of product concentration versus time
resolved the fast and slow phase amplitudes and rate constants for
23-mer/44DDP (ﬁlled square) and 24-mer/44DDP (ﬁlled circle). For
23-mer/44DDP, the following kinetic parameters were extracted:
A1=2.1 0.1nM (7%), k1=10 2s
 1, A2=19 1nM (63%),
k2=0.0009 0.0001s
 1. For 24-mer/44DDP, the following kinetic
parameters were resolved: A1=1.11 0.01nM (3.7%), k1=4.0 
0.7s
 1, A2=3.2 0.4nM (11%), k2=0.00016 0.00003s
 1. The
inset shows product formation within 15s, which corresponds to the
fast phase.
Nucleic Acids Research, 2008, Vol. 36, No. 12 3873phase with a rate constant of 5.7 0.6s
 1 in the presence
of an unlabeled DNA trap (data not shown).
DISCUSSION
Kineticbasis of cisplatin resistance mediated by aY-family
DNA polymerase
The clinical eﬀectiveness of cisplatin chemotherapy is
limited by drug resistance in which the process of TLS is
a likely factor (21,24,25,52,53). The newly discovered
Y-family DNA polymerases are suspected to participate in
the bypass of platinated-DNA adducts (5–7). Of the four
human Y-family polymerases, PolZ is the likely candidate
responsible for bypassing platinated-DNA adducts in vivo
(13,14). Interestingly, results from P. Blum’s laboratory
showed that a Dpo4-knockout cell line of S. solfataricus is
more sensitive to cisplatin treatment than the wild-type
strain (personal communication). This suggested that
Dpo4, the lone Y-family DNA polymerase in S. solfata-
ricus, participates in the resistance of cisplatin in vivo.T o
explore the kinetic basis of cisplatin resistance caused by
the Y-family enzyme and to better understand double-
base lesion bypass, we investigated the bypass of a site-
speciﬁcally placed cisplatin-d(GpG) adduct catalyzed by
Dpo4. Consistent with the in vivo observation, Figure 1B
showed that Dpo4 was able to incorporate nucleotides
opposite and extend from the cisplatin-d(GpG) adduct.
However, the observation of intermediate product accu-
mulation ignited further interest into elucidating the
mechanistic basis of Dpo4 pausing during the insertion
step as well as the lack of signiﬁcant pausing during the
downstream extension steps.
X-ray and NMR structural studies reveal numerous
distortions when cisplatin forms a covalent linkage with
two neighboring guanines in duplex DNA (48–50).
Notable structural consequences in accommodating an
intrastrand cross-link include the following: (i) DNA is
signiﬁcantly bent ( 40–808) over several base pairs,
(ii) the minor groove is widened and ﬂattened, (iii) there
is a 26–498 dihedral angle between coordinated d(GpG)
bases, (iv) the platinum atom is displaced from the gua-
nine plane by  1A ˚ , (v) A- and B-forms of DNA are
observed, (vi) the d(GpG) bases are propeller twisted yet
maintain Watson–Crick hydrogen bonding with the com-
plementary strand and (vii) the amine group of cisplatin is
hydrogen bonded to the phosphate oxygen of the DNA
backbone (49,50). Despite the distorted DNA structure,
the binding aﬃnity of the binary complex was only
modestly weakened ( 3-fold) at the lesion site and one
base downstream of the lesion (Table 2). Instead, DNA
structural perturbations had a more profound eﬀect on
nucleotide incorporation eﬃciency and ﬁdelity.
All incorporation events upstream of the lesion were
catalyzed by Dpo4 with an eﬃciency comparable to
undamaged DNA (Table 3). Upon encountering the
cisplatin-coordinated 30-dG, Dpo4 correctly inserted
dCTP with a 72-fold decrease in eﬃciency relative to an
undamaged dG base (Tables 3 and 4). The kinetic
parameters suggested that weak dCTP binding (11-fold)
accounted more for the reduction of catalytic eﬃciency
than did the rate of dCTP incorporation (7-fold).
However, the substrate speciﬁcity of dCTP incorporation
at the cisplatin-coordinated 50-dG was decreased by
860-fold due to a decrease in the rate of incorporation
by 105-fold (4.5s
 1!0.043s
 1) (Tables 3 and 4). The
weak apparent ground-state binding aﬃnity (1/Kd)o f
dCTP at both strong pause sites may indicate poor base
stacking. Using pyrene nucleoside 50-triphosphate, we
have shown previously that base stacking governs the
binding aﬃnity of a nucleotide opposite an abasic site
(37), undamaged DNA of a recessed primer/template
substrate (42) and undamaged DNA of a blunt-end
substrate (42). Due to the covalent linkage of cis-
diammineplatinum(II) with the adjacent guanine residues,
the orientation of dCTP, the templating base and the
30-OH may preclude normal base stacking interactions,
thereby weakening the binding aﬃnity of an incoming
nucleotide.
Interestingly, as we completed our kinetic studies
reported here, an X-ray crystallographic study of yeast
PolZ (yPolZ) in the presence of a cisplatin-d(GpG)
intrastrand cross-link and dCTP or dATP was published
(54). This study provided a structural basis for the two
aforementioned slow translesion steps: the incoming
nucleotide’s distance from the 30-OH of the modeled
primer terminus is unfavorably long (5A ˚ and 7.5A ˚ for the
ﬁrst and second elongation steps, respectively) (54).
However, the ineﬃcient bypass catalyzed by Dpo4 may
originate from a diﬀerent combination of subtle structural
factors. Further kinetic analysis uncovered two distinct
kinetic phases occurring at the active site of Dpo4 in the
presence of a DNA trap. Bypassing the cisplatin cross-
linked 30-dG showed the rapid incorporation (10s
 1)o f
dCTP for a small percentage (7%) of the Dpo4 23-mer/
44DDP complexes and then a larger percentage (63%)
gradually turned over (0.0009s
 1) to product (Table 5 and
Figure 5). These results suggested the existence of two
distinct binary complexes: E Dn
P (productive) and E Dn
N
(nonproductive) (Scheme 1). Initially, 7% of the Dpo4-
bound species achieved a productive binary complex that
was competent for catalysis, while 63% existed as a
nonproductive binary complex that slowly converted into
a productive state without dissociating (Table 5 and
Figure 5). For the remaining 30%, which did not generate
product, these Dpo4-bound species were either arrested in
a ‘dead-end’ state or simply dissociated and diluted by the
nonradiolabeled DNA trap. Structural evidence of yPolZ
in a pre-elongation and elongation ternary complex at the
cisplatin-coordinated 30-dG position supports the exis-
tence of the nonproductive and productive modes,
Table 5. Biphasic kinetic parameters of dCTP incorporation
into cisplatin-modiﬁed DNA
DNA
substrate (P/T)
k1 (s
 1)A 1 (nM) k2 (s
 1)A 2 (nM)
23-mer/44DDP 10 2 2.1 0.1
(7%)
0.0009 0.0001 19 1
(63%)
24-mer/44DDP 4.0 0.7 1.11 0.01
(3.7%)
0.00016 0.00003 3.2 0.4
(11%)
3874 Nucleic Acids Research, 2008, Vol. 36, No. 12respectively, described by the kinetic data herein (54).
Unfortunately, the biphasic kinetic assay cannot distin-
guish between the presence of binary and ternary
complexes in a productive or nonproductive state due to
the rapid binding of an incoming nucleotide. Thus, in light
of the ternary species observed in the X-ray crystal
structures of yPolZ, the kinetic scheme derived from
biphasic kinetic analysis (Scheme 1) has been expanded to
include the possible existence of productive and non-
productive ternary complexes as shown in Supplementary
Scheme 1 (54). Lastly, it is possible that there is a hetero-
geneous mixture of various nonproductive binding modes
as binary and/or ternary complexes.
The biphasic kinetic trace during the bypass of the
cisplatin-coordinated 50-dG revealed a diﬀerent trend than
the cisplatin-coordinated 30-dG as catalyzed by Dpo4
(Table 5 and Figure 5). Although dCTP was still rapidly
incorporated (4s
 1) by a small percentage (3.7%) of
productively bound Dpo4 species, a greater percentage
( 96%) was either present as a nonproductive binary
complex (11%) or dissociated in favor of binding to the
nonradiolabeled DNA trap (85%) (Table 5 and Figure 5).
HIV type 1 reverse transcriptase (HIV-1 RT), an enzyme
with low ﬁdelity and processivity, exhibits a similar
biphasic kinetic trend as Dpo4 in which the total ampli-
tude for the ﬁrst ( 25%) cross-linked guanine is greater
than the second ( 2%) (41). In contrast, the total ampli-
tudes for an exonuclease-deﬁcient mutant of T7 DNA
polymerase (T7 exo
 ) were 2.6%, 3.0% and 4.6% for
correct nucleotide incorporation into 23-mer/44DDP,
24-mer/44DDP, and 25-mer/44DDP, respectively (41).
Together, these biphasic kinetic data illustrate the
spectrum of cisplatin-d(GpG) bypass in which the rigid
active site of a replicative polymerase (e.g. T7 exo
 )i s
blocked, while ﬂexible active sites are more suitable for
TLS (e.g. Dpo4 and HIV-1 RT). Despite possessing
ﬂexible active sites, not all human Y-family polymerases
can independently bypass a cisplatin–DNA adduct in vitro
(8–11,15–17). Thus, active site ﬂexibility does not insure
lesion bypass. Presumably, the ﬂexible active site of PolZ
can readily accommodate productive binary and/or
ternary complex formation, while the active sites of Poli
and Polk fail to achieve proper alignment for nucleotidyl
transfer. Interestingly, the same mechanism shown in
Scheme 1 occurs during the bypass of an abasic site, a
model single-base lesion, catalyzed by Dpo4 (37). Thus,
Scheme 1 or Supplementary Scheme 1 represents a
universal kinetic mechanism for the bypass of single-
base and double-base DNA lesions catalyzed by a variety
of translesion DNA polymerases including the Y-family
enzymes and HIV-1 RT.
From the overall reaction rate measured under single-
turnover conditions, the individual contribution of the
productive and nonproductive binary complexes can be
extracted, since product formation under single-turnover
conditions is comprised of all productive and nonproduc-
tive binding states. For example, opposite the cisplatin
cross-linked 30-dG, contributions from the fast phase of
nucleotide incorporation [(10s
 1) (7% reaction ampli-
tude)] and the slow phase [(0.0009s
 1) (63% reaction
amplitude)] are predicted to yield an overall product
formation rate of 0.70s
 1. Since the biphasic kinetic
assays in Figure 5 were performed at sub-saturating
concentrations of dCTP (1.0mM), the observed rate at the
ﬁrst strong pause site was calculated to be 0.70s
 1 based
on the apparent kp and Kd values for dCTP (Table 3)
substituted into Equation 3. This value of 0.70s
 1
matched 0.70s
 1 estimated from the biphasic kinetic
parameters. Thus, the observed rate constant extracted
from single-turnover kinetic analyses was dominated by
the rate constant of the fast phase, k1. A similar
connection between single-turnover and biphasic kinetic
assays was obtained for abasic lesion bypass (37). Due to
the complication of at least two phases occurring within a
single turnover, an apparent rate of nucleotide incorpora-
tion and an apparent equilibrium dissociation constant of
an incoming nucleotide was obtained at the strong pause
sites (Table 3). An advantage of the biphasic kinetic assay
is that the fast and slow phases can be discerned in the
presence of a DNA trap. Thus, the combination of single-
turnover experiments and the DNA trap assay is a
powerful approach to elucidate the detailed kinetic
mechanisms of lesion bypass.
To complete the TLS process, Dpo4 was able to extend
the primer beyond the lesion, although there were down-
stream events in which Dpo4 appeared to pause slightly.
These ‘weak’ pause sites appeared when incorporating
dNTPs 1, 2, 3, 5 and 6 positions downstream from the
cisplatin-coordinated 50-dG (Figures 1B and 4A).
DiﬀerentialdomaininteractionsofDpo4withthedamaged
DNA substrate may account for this unusual cyclic
pattern. For instance, the little ﬁnger, thumb and/or
linker region may be orienting the cisplatinated DNA
into the most stable conformation, but the templating base
within the active site interior may not be properly aligned
for nucleotidyl transfer. As the DNA helix turns and the
distance between the lesion and the Dpo4 active site
increases,thisdownstreameﬀecteventuallydissipatedafter
seven nucleotide incorporations (Table 3 and Figure 4A).
Steady-state kinetic data show that human PolZ
eﬃciently inserts dCTP opposite cisplatin-d(GpG)
adducts, but the extension step is impaired (8,11). In con-
trast, human Poli and Polk are inhibited by a cisplatin-
d(GpG) adduct (15–17). Dpo4 exhibited a diﬀerent
pattern during TLS in which the eﬃciency of dCTP inser-
tion was decreased, particularly at the cisplatin-coordi-
nated 50-dG lesion and the subsequent extension step was
only modestly reduced (Table 3). Notably, Dpo4 seemin-
gly behaved as a hybrid of human Poli, Polk and PolZ:
Dpo4 catalyzed synthesis was problematic at the lesion
similar to Poli and Polk yet paused during the extension
period like PolZ (8,11,15–17).
Mutagenic potential ofacisplatin-d(GpG) adduct
Several groups have investigated the mutational spectra of
cisplatin in eukaryotic cell-based assays as well as in vivo
(43–47). At cisplatin-d(GpG) cross-links, some highlights
of the reported mutation spectra include: (i) single-base
substitutions, insertions and deletions, (ii) G:C!A:T
transitions and G:C!T:C transversions and (iii) most of
the mutagenic events were located opposite the lesion
Nucleic Acids Research, 2008, Vol. 36, No. 12 3875(45–47). These results suggest that the overall TLS process
by human DNA polymerases is error-prone in the
presence of cisplatin-damaged DNA, although, individual
DNA polymerases (e.g. PolZ) may replicate in an error-
free manner. For the model Y-family polymerase, the
likelihood of misincorporation increased, as the ﬁdelity of
Dpo4 decreased up to two orders of magnitude when
compared to the ﬁdelity studies of normal DNA
(Figure 4B) (36). For both cisplatin cross-linked guanines,
dATP was promiscuously inserted (Table 3). This pre-
ferential misinsertion of dATP over dTTP and dGTP may
be due to a hydrogen bond between the C6 amino group
of dATP and the C6 carbonyl oxygen of cisplatin-dG.
This observation is depicted in the cisplatin-coordinated
50-dG elongation structure of yPolZ with dATP (54). In
regards to substrate speciﬁcity, Dpo4 selectively incorpo-
rated dCTP over dATP by 163- and 13-fold against
the cisplatin-coordinated 30-dG and 50-dG, respectively
(Table 3). Fidelity during the extension steps was relatively
normal except for the ‘weak’ pause site at 26-mer/44DDP,
whereby dATP was preferentially incorporated over the
other incorrect dNTPs opposite template dC (Table 3 and
Figure 4). Typically with an undamaged DNA substrate,
Dpo4 discriminates between dGTP and dATP opposite
template dC by 2100-fold (36); however, a discrimination
factor of only 170-fold was achieved with 26-mer/44DDP
(Table 3). Interestingly, the 50 template base is dT which
may explain the preferential selection of dATP. In general,
the promiscuity of Dpo4 appeared to be conﬁned to the
site of the lesion, as downstream events were essentially
error-free (Table 3 and Figure 4B). More importantly, this
result suggested that human Y-family DNA polymerases
may generate mutations during cisplatin bypass, thereby
promoting the risk of secondary malignancies observed in
cisplatin-treated cancer patients.
The misinsertion frequency of Dpo4 on a cisplatin-
d(GpG) substrate quantitatively suggested that the overall
bypass process was potentially error-prone. Although the
ﬁdelity of a DNA polymerase may be less stringent at the
cisplatin-d(GpG) lesion, such as what we have observed
with Dpo4, other repair pathways may compensate by
preferentially recognizing misincorporations opposite the
cisplatin-d(GpG) cross-link. For example, the mismatch
repair complex preferentially distinguishes a mismatch
depending on the base pair opposite the lesion
(dT>dG>dA) as well as the type of cisplatin–DNA
adduct [cisplatin-d(GpG)>cisplatin-d(ApG)>cisplatin-
d(GpNpG) (55,56)]. Thus, in the presence of ciplatin, the
overall integrity of genomic DNA is a complex function of
several diﬀerent cellular pathways.
Kineticcomparison of double-base lesion bypass
Using pre-steady state kinetics, the mechanism of correct
nucleotide incorporation opposite a cis-syn thymine–
thymine (TT) dimer catalyzed by yPolZ is kinetically
eﬃcient, which is in contrast to the bypass mechanism of
cisplatin-d(GpG) catalyzed by Dpo4 presented here (57).
Relative to undamaged DNA, the substrate speciﬁcity for
correct dNTP insertion opposite cisplatin-d(GpG) is
decreased 72- to 860-fold (i.e. ineﬃcient) for Dpo4
versus 1.2- to 6-fold (i.e. eﬃcient) for the TT lesion and
yPolZ (Table 3) (57). However, binary complex formation
was not signiﬁcantly weakened for either enzyme despite
the lesion-induced structural perturbations of the DNA
helix (Table 2) (48–50,57,58). Examination of the crystal
structures containing the DNA lesion in complex with
a polymerase and dNTP suggest hydrogen bonding is a
critical factor during TLS (54,59). Further kinetic and
structural evidence is a requisite in order to fully under-
stand the diﬀerences in the bypass eﬃciency and accuracy
of a TT dimer and a cisplatin-d(GpG) adduct. Since yPolZ
is dramatically more eﬃcient at bypassing a TT lesion,
the productively bound ternary complex in Scheme 1 is
likely dominant over the nonproductively bound ternary
complex during TLS.
In summary, this study elucidated the kinetic mecha-
nism of Dpo4 bypassing an important double-base lesion:
a cisplatin-d(GpG) intrastrand cross-link. Although Dpo4
was capable of bypassing this double-base lesion at 378C,
the TLS process was kinetically characterized as relatively
ineﬃcient and error-prone, especially opposite the cis-
platin-coordinated 50-dG. Using the knowledge gleaned
from this study, improved platinum-based anticancer
drugs may be rationally designed.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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